Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer
Yu cu trnh nh sng nh hng ca nh sng ti thuc BPC 157 nhy cm vi nh sng
To view a copy of this licence, visit About this article Cite this article Chang, TT., Lin, ZW., Zhang, LQ
Future research should focus on clinical translation of these platforms to enhance patient outcomes and quality of life
They exist in a regulatory gray area, often sold with labels that say "for research purposes only." This matters for a few reasons: Quality control is inconsistent
Phase 3 trial data shows that ~28.7% average weight reduction is achieved by 68 weeks, with the largest improvements in metabolic markers fasting glucose, A1c, liver fat, blood pressure typically appearing by month 9